Welcome to LookChem.com Sign In|Join Free

CAS

  • or

18951-44-5

Post Buying Request

18951-44-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

18951-44-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 18951-44-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,9,5 and 1 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 18951-44:
(7*1)+(6*8)+(5*9)+(4*5)+(3*1)+(2*4)+(1*4)=135
135 % 10 = 5
So 18951-44-5 is a valid CAS Registry Number.

18951-44-5Relevant articles and documents

Synthesis and cytotoxic effects on pancreatic cancer cells of resveratrol analogs

De Filippis, Barbara,De Lellis, Laura,Florio, Rosalba,Ammazzalorso, Alessandra,Amoia, Pasquale,Fantacuzzi, Marialuigia,Giampietro, Letizia,Maccallini, Cristina,Amoroso, Rosa,Veschi, Serena,Cama, Alessandro

, p. 984 - 991 (2019/05/10)

In this study, a series of resveratrol analogs was synthesized and the effects on the viability of pancreatic cancer cell lines were evaluated. The new molecules were designed by removing the 3- and 5-OH groups of resveratrol, and by incorporating other s

Decarboxylation of α,β-unsaturated aromatic lactones: Synthesis of: E-ortho -hydroxystilbenes from 3-arylcoumarins or isoaurones

Huang, Xihua,Liu, Jie,Sheng, Jianfei,Song, Xianheng,Du, Zhibo,Li, Mingkang,Zhang, Xuejing,Zou, Yong

supporting information, p. 804 - 808 (2018/03/06)

A simple and environmentally friendly strategy for the synthesis of E-ortho-hydroxystilbenes has been established. Two kinds of α,β-unsaturated aromatic lactones, i.e. the 3-arylcoumarins and the isoaurones, could both readily undergo a cascade hydrolyzation/decarboxylation reaction in the presence of KOH in ethylene glycol to afford the desired E-ortho-hydroxystilbenes in moderate to high yields.

SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION

-

Paragraph 0004; 0013, (2016/04/20)

The present invention relates to compounds that modify low density lipoprotein receptor (LDLR) expression. The compounds have the structural formula I shown below: wherein m, R1, n, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with elevated levels of low density lipoprotein cholesterol (LDL-C).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 18951-44-5